Ignite Creation Date:
2024-05-05 @ 11:29 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00051636
Status:
COMPLETED
Last Update Posted:
2012-05-15
First Post:
2003-01-14
Brief Title:
Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Pagets Disease of Bone Including an Extended Observation Period
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
Randomized Double-blind Safety and Efficacy Trial With Intravenous Zoledronic Acid for the Treatment of Pagets Disease of Bone Using Risedronate as a Comparator Including an Extended Observational Period
Status:
COMPLETED
Status Verified Date:
2012-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The core study looked at the effect of Zoledronic Acid given once as an intravenous iv infusion compared to 60 days of oral Risedronate in patients with Pagets disease of bone The effect was demonstrated in the reduction of serum alkaline phosphatase SAP The extended observation period included participants of the core study who responded to treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| ZOL446K2304 | OTHER | Novartis Pharmaceuticals | None |